BDMD Baird Medical Investment Holdings Ltd Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1982444 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-39.2%
TTM net income YoY-319.0%
TTM EPS YoY-271.9%
Revenue 3-yr CAGR-13.7%
Net income 3-yr CAGR—
Margins
Gross margin83.8%
Operating margin-113.7%
Net margin-121.0%
FCF margin-6.2%
EBITDA margin-108.8%
Returns
ROE-76.8%
ROA-36.9%
ROIC (approx.)-50.1%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets55.2%
Debt / equity0.28x
Current ratio1.70x
Interest coverage-72.33x
Cash quality & payout
Operating cash flow / net income0.05x
Accruals ratio-35.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $22.54M | $37.04M |
| Cost of revenue | $3.65M | $4.38M |
| Gross profit | $18.88M | $32.65M |
| R&D expense | $20.13M | $6.17M |
| SG&A expense | $14.12M | $7.10M |
| Operating income | -$25.63M | $15.32M |
| Interest expense | $354,341 | $388,613 |
| Pretax income | -$26.37M | $14.09M |
| Income tax | $1.17M | $1.49M |
| Net income | -$27.28M | $12.45M |
| EBITDA | -$24.53M | $16.45M |
| EPS (basic) | -0.98 | 0.57 |
| EPS (diluted) | -0.98 | 0.57 |
| Weighted avg. shares (diluted) | 27.79M | 21.83M |
| Balance sheet | ||
| Cash & equivalents | $178,321 | $2.97M |
| Receivables | $42.53M | $46.58M |
| Inventory | $1.09M | $1.30M |
| Current assets | $54.97M | $61.42M |
| PP&E, net | $6.37M | $7.14M |
| Goodwill | $60,303 | $57,772 |
| Intangibles | $8,626 | $16,528 |
| Total assets | $69.70M | $77.96M |
| Current liabilities | $32.36M | $34.62M |
| Short-term debt | $2.64M | $867,772 |
| Long-term debt | $6.09M | $3.44M |
| Total debt | $8.72M | $4.31M |
| Total liabilities | $38.48M | $38.20M |
| Shareholders' equity | $31.37M | $39.66M |
| Net debt | $8.54M | $1.34M |
| Shares outstanding | 30.75M | 25.56M |
| Cash flow statement | ||
| Operating cash flow | -$1.34M | -$6.31M |
| Capital expenditure | $42,315 | $2.85M |
| Free cash flow | -$1.39M | -$9.17M |
| Investing cash flow | -$42,315 | -$2.47M |
| Financing cash flow | -$1.39M | $10.33M |
| Depreciation & amortization | $1.10M | $1.14M |
| Stock-based compensation | $17.47M | $0 |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.